Compare FNKO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | RZLT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.1M | 187.3M |
| IPO Year | 2017 | N/A |
| Metric | FNKO | RZLT |
|---|---|---|
| Price | $3.50 | $2.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $7.13 | ★ $12.33 |
| AVG Volume (30 Days) | 645.8K | ★ 14.6M |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $928,842,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $1.07 |
| 52 Week High | $14.65 | $11.46 |
| Indicator | FNKO | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 64.86 | 31.54 |
| Support Level | $2.95 | $1.78 |
| Resistance Level | $3.11 | $2.82 |
| Average True Range (ATR) | 0.17 | 0.49 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 97.35 | 15.55 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.